Lisheng Pharmaceuticals (002393.SZ): Apomistel approved marketing license application

Zhitong Finance App News, Lisheng Pharmaceutical (002393.SZ) announced that the company's subsidiary, Tianjin Central Pharmaceutical Co., Ltd. (“Central Pharmaceutical”), has received the “Drug Registration Certificate” issued by the State Drug Administration for 10 mg specifications; the “Drug Registration Certificate” for apomistel tablets 20 mg; and the “Drug Registration Certificate” for apomistel tablets 30 mg. The above drugs have passed the drug marketing license application.

According to the announcement, the indications for apamistel tablets are: This product is used to treat adult patients with moderate to severe plaque psoriasis who meet the indications for light therapy or systematic treatment.